The Gynecology Team Participated in the 13th Asian Congress on Endometriosis 2025
The 13th Asian Congress on Endometriosis (ACE 2025) will take place from October 31 to November 3, 2025, in Colombo, Sri Lanka. Under the theme “Empowering Women, Optimizing Care: The Future of Endometriosis and Adenomyosis,” the congress brings together gynecologists, researchers, and clinicians from around the world. For the first time, joint workshops and panel discussions have been organized in collaboration with endometriosis societies from Europe and the United States, fostering in-depth exchanges on the latest research and clinical advances.
As a leading institution in Chinese gynecology, the Endometriosis Team from WHZJU was invited to present at this international forum, showcasing their scientific and clinical expertise.
At ACE 2025, Professor Xinmei Zhang delivered an insightful oral presentation titled “A Safer Surgical Path for Rectal Endometriosis Nodules: Preserving the Mesentery.” This groundbreaking research introduces a novel surgical technique for rectal endometriosis that prioritizes patient safety and minimizes postoperative complications. This method emphasizes maintaining anatomical structures vital for blood supply and nerve function, which are often compromised in conventional stapled resections. The study compared this new approach with traditional stapled resections, evaluating postoperative complications, recovery times, and functional outcomes. Results from the mesentery-preserving group were compared with those from a traditional stapled resection group, with both groups comprising patients of similar characteristics. This mesentery-sparing technique offers a safer surgical pathway, ensuring enhanced functional outcomes by safeguarding the mesentery and other key structures during surgery, ultimately benefiting patients.
Dr. Xinxin Xu gave an oral presentation titled “Dydrogesterone Alleviates Endometriosis Progression by Suppressing Neuroangiogenesis via CCL5 Downregulation”. Endometriosis is a chronic condition affecting millions of women worldwide leading to pain, infertility, and reduced quality of life. While dydrogesterone has been used since the 1960s to treat endometriosis, its molecular mechanisms remain incompletely understood. The results indicated that dydrogesterone alleviates endometriosis-related pain and lesion growth by targeting CCL5-mediated neuroangiogenesis. Also, dydrogesterone treatment not only reduced plasma CCL5 levels but also improved mechanical and thermal pain thresholds in mice. This provides a molecular basis for its clinical efficacy and supports its use in women seeking pregnancy. This study sheds new light on the therapeutic potential of dydrogesterone and opens avenues for more targeted and effective treatments for endometriosis.
Dr. Sun Man delivered an oral presentation titled “New MRI-based Classification of Adenomyosis: Correlation with Symptom Severity and a Treatment-Oriented Scoring System. Magnetic Resonance Imaging (MRI) is central to the diagnosis of adenomyosis. This retrospective study introduced a novel MRI-based classification linking uterine characteristics to clinical manifestations. Cases were categorized into Class I–III by uterine volume, and Configurations A–F by anatomical location and lesion extent (e.g., myometrial layers, serosal/cervical involvement). The study identified structural factors contributing to dysmenorrhea and heavy menstrual bleeding, and assessed how specific MRI subtypes influence infertility and miscarriage risks. By correlating MRI classifications with treatment outcomes, the team developed a scoring system to support personalized management of adenomyosis.
This participation not only highlighted the international presence of Zhejiang University Women’s Hospital, but also strengthened collaboration between Chinese and Asian experts in obstetrics and gynecology. Guided by science and innovation, the team continues to contribute Chinese insights to the global effort of improving endometriosis care.
Moving forward, the team will continue to focus on patient needs, promote interdisciplinary collaboration, and enhance international exchange—translating cutting-edge research into compassionate, efficient clinical practice, and advancing the vision of lifelong health for women worldwide. We look forward to the next stage, when the “Voice of Zhejiang” resonates across the globe once again!
